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West Nile virus causes febrile illness in humans with a proportion of cases progressing to meningoencephalitis, encephalitis, hepatitis, and
death. Isolates of the virus fall into two genetic lineages, with differences in neuroinvasiveness for mice occurring between strains within both
lineages. We used DNA microarrays to compare gene expression in mice infected peripherally with seven lineage 1 and 2 strains confirmed
to be of either high or low neuroinvasiveness in mice and associated with severe or benign infection in humans and birds. The 4 strains with
highest neuroinvasiveness induced increased expression of 47 genes in the brain, 111 genes in the liver, and 70 genes in the spleen, relative to
the 3 least neuroinvasive strains. Genes involved in interferon signaling pathways, protein degradation, T-cell recruitment, MHC class I and II
antigen presentation, and apoptosis were identified that may have both pathogenic and protective effects, but increased expression of certain
acute proteins, central nervous system specific proteins and proteins associated with T-cell hepatitis, implicate mechanisms related to exalted
virulence.
Published by Elsevier Inc.Keywords: West Nile virus; Neuroinvasion; Strain virulence; Encephalitis; DNA microarrays; Gene expressionIntroduction
West Nile virus (WNV), a mosquito-borne Flavivirus, is
widely distributed in Africa, Asia, and Europe, and has
recently spread to the Western Hemisphere where its
presence was recognized in the northeastern United States
in 1999 (Lanciotti et al., 1999; Smithburn et al., 1940). Most
human infections result in mild dengue-like illness that
resolves in 3–6 days (Monath and Heinz, 1996), but a
subset of cases progresses to meningitis, encephalitis, or a
paralytic poliomyelitis-like syndrome (Leis et al., 2003). A
few cases of hepatitis have also been documented (Burt et
al., 2002; Georges et al., 1987). Recent outbreaks of WNV
infection in the USA, Eastern Europe, and Israel have been0042-6822/$ - see front matter. Published by Elsevier Inc.
doi:10.1016/j.virol.2005.07.013
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E-mail address: mariav@nicd.ac.za (M. Venter).characterized by relatively high rates of potentially fatal
neurological complications, especially in elderly human
patients, birds, and horses (Cantile et al., 2001; Durand et
al., 2002; Murgue et al., 2001; Steinman et al., 2002). In
Southern Africa, WNV is widely endemic, and human
infections tend to be sporadic, with large epidemics
occurring only when unusually high rainfall or hot weather
favors breeding of the mosquito vectors (McIntosh, 1980).
The number of human infections with WNV confirmed in
southern Africa has remained constant at approximately 5–
15 per year for the past two decades, but only a proportion
of suspected cases are subjected to laboratory investigation.
Despite the low number of infections recorded, a few cases
of severe disease have been recognized, including fatal
hepatitis and non-fatal encephalitis in humans, and fatal
encephalitis in a horse and a dog (Burt et al., 2002).
The perceived increase in severity of infections in the
Northern Hemisphere raised the question of whether WNV05) 119 – 140
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whether the virulence of the virus had previously been
underestimated. The demonstration that there are 2 phylo-
genetic lineages of WNV, with lineage 1 including isolates
from North Africa, Europe, Asia, and North America, as
well as FKunjin virus_ from Australia, while lineage 2
consists solely of isolates from Southern Africa and
Madagascar, supported the perception that the emergence
of increased virulence was associated with lineage 1 strains
in the Northern Hemisphere (Lanciotti et al., 1999).
However, comparison of the phylogenetic relationships
and neuroinvasiveness in mice of South African and North
American WNV isolates indicated that pathogenicity is
genotype specific and not related to lineage, source of
isolate, geographic distribution, passage level, or year of
isolation (Burt et al., 2002; Beasley et al., 2002).
Despite the demonstration of differences in neuro-
invasiveness between WNV strains, little is known about
host gene response in benign, neurovirulent, or hepatitic
infections. Although DNA microarray technology makes it
possible to detect changes in host gene expression, and to
reveal molecular pathways that govern viral pathogenesis,
most studies have been restricted to cell cultures, and little
is known about response in the intact host (Johnston et al.,
2001). The only studies involving mosquito-borne flavivi-
ruses relate to Genechip analysis of response to dengue
virus infection in cultures of human umbilical vein
endothelial cells, and WNV infection of human embryonic
kidney cells (Warke et al., 2003; Fredericksen et al., 2004)
plus human glioma cells (Koh and Ng, 2005). Changes in
mRNA expression patterns in response to viruses that
infect the nonrenewable cell populations of the central
nervous system (CNS) may, however, be better studied in
the intact host rather than in cell cultures (Saha and
Rangarajan, 2003).
To identify candidate host genes associated with WNV
pathogenesis, we utilized DNA microarray technology to
measure gene transcription (mRNA levels) in mice infected
with WNV phylogenetic lineage 1 and 2 strains, focusing on
brain, liver, and spleen tissues. Six strains selected for study
were known to have caused either severe or benign infection
in humans and birds, while the seventh was a mosquitoTable 1
Characteristics of West Nile virus strains included in the present study
Strain Phylogenetic
lineage
Origin Source; context Cu
le
SPU116/89 2 South Africa, 1989 Human; fatal hepatitis M
H442 2 South Africa, 1958 Human; benign disease M
NY385/99 1 USA, 1999 Bird; fatality TC
NY2001Hu 1 USA, 2001 Human; fatal encephalitis TC
AN4766 1 Ethiopia, 1976 Bird; survey U
AR381/00 2 South Africa, 2000 Human; benign disease M
MRM16*** 1 Australia, 1960 Mosquito; survey M
* M = mouse, TC = cell culture.
** AST = average survival time (days) after administration of 104 TCID50 in
*** Kunjin virus.isolate. All were characterized as having either high or low
neuroinvasiveness in mice. WNV infection resulted in
significant changes in the expression of many genes in the
brain, generally correlating with neuroinvasiveness. Al-
though WNV RNA levels were much lower than those in
the brain, similar changes in host gene expression were
detected in the liver and spleen in response to the highly
neuroinvasive strains with many of the genes belonging to
the same functional groups as in the brain.Results
Identification of WNV strains with high and low
neuroinvasiveness
The LD50 values determined for the WNV strains
included in the present study by ip titration in mice ranged
from 0.2 to 1000 TCID50, and following precedence
(Beasley et al., 2002), we chose an arbitrary cutoff value,
50 TCID50, to distinguish 4 more highly neuroinvasive
WNV strains from 3 less neuroinvasive strains (Table 1). As
observed previously (Beasley et al., 2002), there was less
variation in LD50 values between strains following titration
by direct intracerebral inoculation of virus, range 0.1–50
TCID50 (data not shown).
Identification of host genes differentially expressed in WNV
infection
A dose of 10,000 TCID50 was chosen for subcutaneous
inoculation of mice to ensure maximum mortality for all
strains of WNV, and animals were sacrificed on day 5 post-
infection; 1 day before deaths had been recorded with any
strain following ip inoculation. The mean gene expression
in each organ in response to infection with each WNV strain
was compared to expression after mock infection, and genes
that had |2|-fold change for at least 1 strain, and with
values Fpresent_ in at least 60% of the strains, were selected
for further analysis. Using these criteria, 127 differentially
expressed genes were detected in brain tissue, of which 84
had increased expression and 43 decreased expression inlture passage
vel received*
Neuroinvasiveness
for mice
Intraperitoneal
LD50 dose (TCID50)
Intraperitoneal
AST**
4 High 2.0 8.00 T 1.25
2 High 3.2 7.60 T 0.87
2 High 7.9 6.00 T 1.25
2 High 20.0 7.40 T 0.87
nrecorded Low 125.9 9.20 T 0.87
2 Low 316.3 8.00 T 1.25
4 Low 1000 15.60 T 0.79
traperitoneally.
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of which approximately 230 had increased and 120
decreased expression, and 353 genes in spleen of which
94 had increased and 259 decreased expression in all or
most infections relative to the mock-infection group. The
complete list of differentially expressed genes for all strains
may be obtained from us on request.
In order to concentrate on the potentially most important
genes, a t test and cutoff value of >1.64- or <1/1.64-fold
change in expression was used to select genes with greater
expression change in response to infection with the more
highly neuroinvasive relative to the less neuroinvasive
strains. Thus, the number of genes selected was reduced
to 47 in the brain, 111 in the liver, and 70 in the spleen, most
of which had increased expression.
The genes that were significantly altered in brain (A),
liver (B), and spleen (C) are shown in Tables 2A, B, C. Each
of these genes was comprehensively evaluated by manually
sorting through the data and grouping the transcripts
functionally, using PUBMED references, UNIQENE ID,
Locus Link and GO-ontology, as well as the annotation
tools DAVID and EASE (http://david.niaid.nih.gov).
Genes with increased expression in brains of mice infected
with highly neuroinvasive WNV strains
Genes with increased expression in brains of mice in-
fected with the more highly neuroinvasive WNV strains fell
into functional categories known to be involved in immune
response to viral infections (predicted with EASE). These
included interferon (IFN)-pathway-related proteins such as
transcription factors, and IFN-inducible genes such as the
antiviral proteins, protein degradation and antigen presenta-
tion-related genes, extracellular matrix and cell adhesion
proteins, plus chemokines. Other functional categories
included CNS-specific genes and apoptosis-related proteins.
Proteins of unknown function were also identified. Genes
with an average ratio for all highly neuroinvasive strains
relative to less neuroinvasive strains of >5-fold increase
included Stat-1, 2V–5V oligoadenylate synthetase-like 2
(Oasl2), programmed cell death 1 ligand 1 (Pdcd1lg1, alias
B7-H1 or PD-L1), plus a gene, 2900034J12Rik, of
unknown function from the Mus musculus adult male
hippocampus cDNA (RIKEN full-length enriched library,
clone 2900034J12).
IFN-pathway-related genes constituted one of the major
groups with increased expression in the brains of mice
infected with the highly neuroinvasive strains. These
included IFN response genes associated with a two-part
signature (Table 2A) (Shaffer et al., 2001). The first
signature includes the IFN response transcription factors
Stat-1 and Irf1, and genes associated with protein catabo-
lism. Irf1 regulates the IFN-a and -h gene promoters and the
IFN-stimulated response element, while the activity of IFN-
g is mediated through Stat-1 (Qing et al., 2004; Samuel,
2001; Schindler and Darnell, 1995). Genes with increasedexpression involved in protein degradation (Table 2A)
included the ubiquitin-specific protease Usp18, and genes
related to MHC Class I antigen presentation, such as the
proteosome subunit beta type 8 (Psmb8), and TAP binding
protein (Tapbp), which suggests a program dedicated to
tagging, degrading, and presenting intracellular antigens
(Shaffer et al., 2001).
The second IFN signature involves genes that promote
resistance to viral infection (Shaffer et al., 2001), and those
with increased expression included Mx1 and Mx2 (myx-
ovirus resistance 1 and 2), antiviral GTPases, as well as
various members of the Oas family, whose products activate
RNase L, an enzyme that degrades viral RNA (Table 2A)
(Jin et al., 1999, 2001; Nagata and Mibayashi, 1997).
However, the gene with the greatest average increase in
expression in the brains of mice infected with the more
highly neuroinvasive strains, 14-fold, was the IFN-induced
protein with tetratricopeptide repeats 2 (Ifit2), a gene of
unknown function which also increases significantly in
human embryonic kidney cells upon infection with tick-
borne encephalitis virus (Gavrilov et al., 2003). Less well-
characterized genes encoding GTP-related proteins with
antiviral functions which also had increased expression in
brain in the more highly neuroinvasive infections included
IFN-induced protein 1 (Ifi1), guanylate binding proteins 2
and 3 (Gbp2, Gbp3), as well as the ubiquitin-like molecule
G1p2, alias Isg15 or IP17, that functions as a neutrophil
chemotactic factor (Owhashi et al., 2003). Increased levels
of G1p2 following viral infection may be associated with
ependymal cell necrosis which in turn results in hydro-
cephalus, suggesting a role in the pathogenesis of encepha-
litis (Kim and Zhang, 2003).
Evidence was also found for increased activation of T-
cell chemotactive agents by the highly neuroinvasive
strains. The chemokine CXCL11/I-TAC, was the gene with
the second highest average increase in expression, 8-fold, in
the brains of infected mice. CXCL11 is chemotactic for
interleukin-activated T cells, neutrophils or monocytes, and
natural killer cells (NK cells) and may play an important
role in CNS diseases involving T-cell recruitment (Entrez
protein accession number Q9JHH5) (Huang et al., 2000;
Salmaggi et al., 2002; Widney et al., 2000).
A number of CNS-specific proteins with potentially
pathogenic roles were increased in the brains of mice
infected with the highly neuroinvasive strains. Apod, with
an average increase of 4-fold in the more highly neuro-
invasive infections (Table 2A), is an acute phase protein
involved in removal of lipids during nerve cell degeneration
and provision of lipids during the regenerative phase
(Reindl et al., 2001). The glial fibrillary acidic protein
(Gfap) had an average increase of 2.5-fold and reportedly
increases following surgery or viral infection, and is
associated with astrocyte activation/reactive astrocytosis
(gliosis) in the brain as a neuroprotective response, possibly
through reducing the blood–brain barrier permeability,
although the exact mechanisms underlying this response
Table 2A
Genes with 1.62 or 1/1.62-fold change in expression on average in brains of mice following subcutaneous infection with 4 highly neuroinvasive strains of WNV relative to 3 less neuroinvasive
strains
Classification Function Gene Description UniGene Fold change in gene expression induced by each WNV
strain in infected mice relative to mock-infected mice
Average fold
change induced
by highly
vs. less
neuroinvasive
strains
SPU
116/89
H 442 NY
385/99
NY
2001Hu
AN
4766
AR
381/00
MRM
16
Transcription
factor
IFN inducible,
MHC class I
Irf1 Interferon regulatory factor 1 Mm.1246 6.68 6.29 2.21 3.59 1.34 0.94 1.97 3.42
IFN inducible Isgf3g Interferon dependent positive acting
transcription factor 3 gamma
Mm.2032 3.33 3.07 2.81 3.42 1.64 0.8 2.91 2.26
IFN inducible Stat-1 Signal transducer and activator
of transcription 1
Mm.277406 12.76 10.32 6.3 9.41 2.96 0.9 1.05 6.37
Protein
degradation
Ubiquitin Usp18 Ubiquitin specific protease 18 Mm.27498 11.56 9.91 8.57 5.66 2.25 1.59 3.57 4.85
Antigen
presentation
Psmb8 Proteosome (prosome, macropain)
subunit, beta type 8
(large multifunctional protease 7)
Mm.13913 7.12 5.75 2.6 4.43 1.54 0.74 3.89 3.42
Tapbp TAP binding protein Mm.14097 8.7 3.96 2.56 2.98 1.46 1.57 2.43 2.74
Trim26 Tripartite motif protein 26 Mm.34587 1.96 2.02 2.09 1.47 0.89 0.98 1 1.98
Proteases Prss11 Protease, serine, 11 (igf binding) Mm.30156 2.14 1.58 1.46 2.09 0.82 1.14 0.9 1.88
Lipocalins Brain injury Apod Apolipoprotein D Mm.2082 6.05 3.82 3.12 3.3 0.55 1.09 1.41 4.43
IFN inducible
proteins
Scavenger receptor Ppicap Peptidylprolyl isomerase
C-associated protein
Mm.3152 8.2 6.09 3.28 6.33 2.16 1.15 2.91 3.53
GTP-binding Gbp3 Guanylate nucleotide binding protein 3 Mm.1909 17.59 14.33 7.68 8.01 3.54 1.45 1.58 6.08
5830443L24Rik RIKEN cDNA 5830443L24 gene Mm.275893 19.73 10.08 6.55 5.99 2.23 0.96 5.94 5.37
Gbp2 Guanylate nucleotide binding protein 2 Mm.24038 8.85 9.21 3.25 3.93 2.94 1.51 2.94 2.89
GTPase, antiviral Ifi1 Interferon inducible protein 1 Mm.29938 9.86 8.53 5.61 5.44 2.7 1.1 1.68 4.52
Chemotaxis G1p2 Interferon alpha-inducible protein Mm.4950 9.39 5.91 3.75 5.09 2.44 0.43 0.95 5.1
Brain injury Tor3a Torsin family 3, member A Mm.206737 6.06 4.79 2.95 4.4 1.45 1.23 1 3.74
Antiviral Oasl1 2V–5V oligoadenylate synthetase-like 1 Mm.95479 4.08 4.3 2.69 2.84 2.3 1.42 1.75 2.12
Antiviral Oas1g 2V–5V oligoadenylate synthetase 1G Mm.260702 7.14 8.98 2.98 5.15 1.64 1.05 1.31 4.34
Antiviral Mx1 Myxovirus (influenza virus) resistance 1 Mm.227378 12.18 7.93 3.58 5.57 1.65 1.29 1 4.15
Antiviral Oas1b 2V–5V oligoadenylate synthetase 1B Mm.233471 8.41 5.32 3.91 4.56 2.83 2.37 1 2.6
Antiviral
inhibits apoptosis
Igtp Interferon gamma induced GTPase Mm.858 5.38 3.8 2.25 3.23 1.4 1.11 3.43 2.46
Antiviral Mx2 Myxovirus (influenza virus) resistance 2 Mm.14157 5.95 4.44 4.28 3.8 1.97 2.19 1 2.45
Antiviral Ifit2 Interferon-induced protein with
tetratricopeptide repeats 2
Mm.2036 32.5 24.68 6.06 14.07 2.16 0.82 0.97 13.75
Antiviral Oasl2 2V–5V oligoadenylate synthetase-like 2 Mm.27162 27.02 20.3 8.55 16.18 3.02 2.27 1 6.9
Ifitm3 Interferon induced transmembrane protein
3 (Ifitm3), mRNA
Mm.141021 9.23 8.97 5.69 5.44 2.61 0.6 1.46 5.44
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Growth factor Growth factor Ogfr Opioid growth factor receptor Mm.250418 2.79 3.31 2.01 2.47 1.41 0.94 1.54 2.16
Growth arrest
and DNA
damage
Growth arrest and
DNA damage
Gadd45g Growth arrest and DNA-damage-inducible
45 gamma
Mm.9653 2.01 1.82 1.26 1.9 0.77 1.19 1 1.82
Extracellular
matrix and
adhesion
Extracellular matrix
and adhesion
Atp1b2 ATPase, Na+/K+ transporting, beta 2
polypeptide
Mm.235204 2.37 1.79 1.03 1.78 0.72 1.26 0.57 1.92
Chemokine Chemokine CXCL11 Chemokine (C–X–C motif) ligand 11 Mm.131723 29.49 19.72 4.12 7.26 1.33 1.44 1 7.61
Central nervous
system specific
Gfap Glial fibrillary acidic protein Mm.1239 4.25 2.9 1.58 1.94 1.11 0.89 1 2.53
Nefh Neurofilament, heavy polypeptide Mm.297509 2.44 2.5 2.07 1.81 0.93 1.77 1.2 1.86
Phyh Phytanoyl-CoA hydroxylase Mm.27066 1.81 1.37 1.32 1.36 0.87 0.83 0.86 1.64
Apoptosis Downregulate CD8
T-cells
Pdcd1lg1 Programmed cell death 1 ligand 1 Mm.168681 16.69 12.65 6.86 9.03 1.99 1.66 1 5.72
Apoptosis inhibitor Gilz Glucocorticoid-induced leucine zipper Mm.22216 3.1 2.93 1.87 1.52 0.83 1.51 1.44 2
Pro-apoptosis Daxx Fas death domain-associated protein Mm.28118 2.15 1.95 2.07 2.17 1.13 0.91 1 2.02
Pro-apoptosis Scotin Scotin gene (Scotin), mRNA Mm.196533 3.11 3.1 1.74 1.97 1.54 0.76 1 2.29
Unknown
function
Fln29-pending FLN29 gene product Mm.20488 2.29 2.55 1.45 1.71 0.85 0.82 0.99 2.14
2610208M17Rik RIKEN cDNA 2610208M17 gene Mm.230924 2.93 2.38 1.62 1.73 0.97 0.94 1 2.21
Hspa5bp1 RIKEN cDNA 6720481D13 gene Mm.27387 1.85 1.63 1.91 2.79 1.24 1.47 0.69 1.8
AI481500 Expressed sequence AI481500 Mm.33838 0.55 0.59 0.55 0.53 1.09 0.79 1 0.57
Trim34 Tripartite motif protein 34 Mm.219657 2.88 3.11 1.93 1.84 1.75 1.09 1 2.01
0610033I05Rik RIKEN cDNA 0610033I05 gene Mm.28309 5.33 3.81 2.03 2.3 1.31 1.05 1 2.75
Epcs3 Ectoplacental cone, invasive trophoblast giant
cells, extraembryonic ectoderm and
chorion sequence 3
Mm.29795 2.65 2.42 1.25 2.42 0.79 1.33 1 2.03
2510038N07Rik RIKEN cDNA 2510038N07 gene Mm.30552 6.81 7.18 2.42 3.49 1.85 0.91 1.11 3.58
A430056A10Rik RIKEN cDNA A430056A10 gene Mm.30756 13.72 10.93 4.04 5.88 2.69 1.05 3.49 4.36
5830458K16Rik RIKEN cDNA 5830458K16 gene Mm.180157 5.86 3.44 2.46 4.01 1.54 0.92 1.81 3.02
Mus musculus adult male hippocampus
cDNA, RIKEN full-length enriched library,
clone:2900034J12, full
11.07 7.41 4.82 7.35 2.53 0.7 2.51 5.05
9830147J24Rik RIKEN cDNA 9830147J24 gene Mm.45740 8.9 6.77 3.47 4.43 1.89 1.51 4.39 3.1
The fold change induced by infection with each WNV strain relative to mock infection is shown in a separate column, and the average change induced by the 4 more highly relative to the 3 less
neuroinvasive strains is shown in the last column.
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Table 2B
Genes with 1.62 or 1/1.62-fold change in expression on average in livers of mice following subcutaneous infection with 4 highly neuroinvasive strains of WNV relative to 3 less neuroinvasive strains
Classification Function Gene Description UniGene Fold change in gene expression induced by each WNV
strain in infected mice relative to mock-infected mice
Average fold
change induced
by highly
vs. less
neuroinvasive
strains
SPU
116/89
H 442 NY
385/99
NY
2001Hu
AN
4766
AR
381/00
MRM
16
Transcription
factor
Transcription factor,
T-lymphocyte
suppressor
Trim30 Tripartite motif protein 30 Mm.295578 7.23 5.32 4.54 6.19 2.88 1.66 1.02 3.55
Transcription
factor, repressor
Rest RE1-silencing transcription factor Mm.28840 2.69 2.01 1.3 1.62 1.26 0.6 0.71 2.08
Transcription factor,
IFN regulator
Irf7 Interferon regulatory factor 7 Mm.3233 5.96 8.88 5.92 5.36 3.84 1.5 1 3.93
IFN regulator,
liver failure
Irf1 Interferon regulatory factor 1 Mm.105218 2.01 2.71 1.58 2.34 1.23 0.99 1.37 1.85
Transcription factor,
CD4 and NK inducer
Stat-1 Signal transducer and activator of
transcription 1
Mm.277406 6.75 3.49 4.35 6.27 3.66 1.31 1.76 3.03
Transcription factor
activity
Mga MAX gene associated Mm.87532 4.25 4.7 3.06 3.48 2.47 0.99 0.94 2.89
Signal
transduction
Signal transduction Gna13 Guanine nucleotide binding protein, alpha 13 Mm.193925 3.6 2.33 2.07 4.32 1.54 1.21 1.8 2.22
Translation
initiation factor
Eif2c4 Eukaryotic translation initiatEif2c4 Mm.86705 1.14 0.90 0.73 0.46 0.94 0.83 0.58 0.52
Protein transport Snx10 Sorting nexin 10 Mm.294166 2.61 2.24 1.69 1.91 1.31 0.88 1.37 1.85
Fdps Farnesyl diphosphate synthetase Mm.39472 0.32 0.54 0.92 0.86 1.31 1.65 2.37 0.42
Protein targeting Slc16a14 Solute carrier family 16 (monocarboxylic acid
transporters), member 14 (Slc16a14), mRNA
Mm.158754 5.58 7.19 6.79 5.52 6.22 0.9 1.94 3.42
Bagl-pending B aggressive lymphoma Mm.49074 3.44 3.25 4.48 3.8 3.13 1.06 1.34 2.57
Protein synthesis Mrpl34 Mitochondrial ribosomal protein L34 Mm.29489 0.49 0.46 0.56 0.35 0.64 1.11 0.73 0.53
Protein
degradation
Antigen presentation Psmb8 Proteosome (prosome, macropain) subunit, beta
type 8 (large multifunctional protease 7)
Mm.180191 6.11 7.42 4.12 5.4 2.84 1.13 1.55 3.71
Protein modification Ubb Ubiquitin B Mm.282093 2.07 2.32 1.62 1.81 1.17 0.92 0.81 1.95
Protease inhibitor Serpina-10 Serine (or cysteine) proteinase inhibitor, clade A
(alpha-1 antiproteinase, antitrypsin), member 10
Mm.29094 3.39 2.03 1.53 2.01 1.31 0.93 1.22 1.96
Protease inhibitor Serpina-3g Serine (or cysteine) proteinase inhibitor, clade A,
member 3G
Mm.264709 8.19 13.04 3.93 4.19 3.26 2.29 2.17 3.2
Negative regulator
of IFN
Usp18 Ubiquitin specific protease 18 Mm.326911 5.99 8.15 4.66 4.53 2.55 1.32 0.89 4.01
MHC class II Ctss Cathepsin S Mm.3619 3.27 4.08 2.42 2.68 2.23 1.22 1.54 2.1
MHC class I Psme2 Proteasome (prosome, macropain) 28 subunit,
beta
Mm.221303 2.99 2.44 1.94 2.46 1.57 1.08 1.2 2.03
Heparin N-deacetylase/
N-sulfotransferase
activity
(Heparan
glucosaminyl) 1
RIKEN cDNA 1200015G06 gene Mm.181862 0.34 0.4 0.62 0.62 0.83 0.92 0.88 0.55
Antigen presentation Psmb9 Proteosome (prosome, macropain) subunit, beta
type 9 (large multifunctional protease 2)
Mm.347458 6.03 5.08 3.72 4.51 3.41 0.99 1.26 3.14
Ubiquitin-activating
enzyme E1-like
(Ube1l) mRNA RIKEN cDNA 1300004C08 gene Mm.1183 4.08 5.29 3.43 2.58 2 1.5 0.86 2.71
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2510038N07Rik RIKEN cDNA 2510038N07 gene Mm.297393 13.3 7.63 6.3 5.85 3.67 1.16 1.23 5.11
Cpa5 Carboxypeptidase A5 Mm.159276 3.3 2.04 2.28 3.48 2.1 1.31 1.84 1.86
Fbxl6 F-box and leucine-rich repeat protein 6 Mm.275279 3.26 3.54 2.49 2.65 1.62 1.08 1.01 2.5
Ubce8 Ubiquitin-conjugating enzyme 8 Mm.38261 3.12 5.44 2.93 2.65 2.8 1.23 1.51 2.17
Nucleic acid
catabolism
Nt5c3 5V-nucleotidase, cytosolic III Mm.158936 2.41 4.8 1.95 1.59 1.23 0.97 0.61 2.47
Nucleic acid
binding
Transcription
regulation,
DNA silencing
Set7-pending SET domain-containing protein 7 Mm.192111 2.29 1.85 2.03 3.86 1.95 0.93 1.41 1.91
BC013672 cDNA sequence BC013672 Mm.33332 2.9 2.79 3.41 2.52 2.08 1.34 0.49 2.38
D11Lgp2e DNA segment, Chr 11, Lothar Hennighausen 2,
expressed
Mm.271830 6.23 7.06 4.56 7.87 2.64 1.5 1.61 3.65
Rnpc1 RNA-binding region (RNP1, RRM) containing 1 Mm.3865 3.46 3.99 2.1 4.22 2.38 1.38 1.8 2.1
Zbp1 Z-DNA binding protein 1 Mm.116687 5.16 6.9 3.95 4.19 2.39 0.61 1.2 3.96
Miscellaneous Oprs1 Opioid receptor, sigma 1 Mm.22745 0.38 0.45 0.73 0.57 0.94 0.98 0.91 0.54
Fgl1 Fibrinogen-like protein 1 Mm.277955 3.41 1.97 1.01 1.31 0.71 0.43 1.08 2.31
Membrane attack
complex
Mpeg1 Macrophage expressed gene 1 Mm.3999 7.73 3.69 4.14 5.5 3.55 0.53 1.79 3.64
Lipocalins Acute phase,
pathogenic action
Saa2 Serum amyloid A 2 Mm.200941 17.62 10.49 3.34 4.56 1.55 0.75 6.97 4.4
Lipocalins 2310016F22Rik RIKEN cDNA 2310016F22 gene Mm.243758 5.72 4.22 4.95 6.41 3.93 0.9 1.72 3.41
Inflammatory response,
Lipocalins, acute phase
response
Orm3 Orosomucoid 3 Mm.10295 3.31 2.1 1.63 2.71 1.12 0.78 1.3 2.34
Lipid biosynthesis Sc5d Sterol-C5-desaturase Mm.32700 0.36 0.26 0.51 0.58 0.88 0.72 0.82 0.49
Ion transport Atp2a2 ATPase, Ca++ transporting, cardiac muscle,
slow twitch 2
Mm.227583 2.89 3.3 1.96 2.11 1.82 1.62 0.73 1.89
Trpc5 Transient receptor potential cation channel,
subfamily C, member 5
Mm.328379 4.26 7.16 3.27 3.68 2.16 1.6 2.1 2.71
Inflammatory
response
Regulator of
inflammatory cytokines,
induce IFN-gamma
Il18bp Interleukin 18 binding protein Mm.45579 3.71 3.48 2.07 2.69 1.63 0.81 1.33 2.43
IFN-inducible Innate immune response,
liver injury/hepatitis
Lbp Lipopolysaccharide binding protein Mm.218846 3.53 3.23 1.51 1.76 0.99 1.21 1.1 2.14
Enhance virulence Apcs Serum amyloid P-component Mm.330510 3.23 2.35 1.47 1.54 1 0.76 1.15 2.11
Tiarp-pending Tnfa-induced
adipose-related
protein
Mm.31403 4.05 3.47 1.94 2.52 1.49 1.24 1.97 2.07
GTPase Tgtp T-cell specific GTPase Mm.15793 63.83 54.59 24.27 37.29 12.45 1.4 1.94 16.92
GTPase Samhd1 SAM domain and HD domain, 1 Mm.248478 3.17 3.63 1.71 2.58 1.43 0.92 1.02 2.38
GTPase, antiviral Gbp3 Guanylate nucleotide binding protein 3 Mm.1909 9.23 10.04 7.33 6.91 4.51 1.24 1.08 5.09
GTPase, antiviral Gtpi-pending Interferon-gamma induced GTPase Mm.33902 3.51 3.91 3.23 4.19 2.56 0.82 1.43 2.8
GTPase, antiviral Iigp-pending Interferon-inducible GTPase Mm.249850 3.45 3.37 2.9 4.09 3.21 0.61 1.1 2.82
IFN-inducible
GTP binding
Gbp2 Guanylate nucleotide binding protein 2 Mm.24038 5.06 4.16 1.66 2.76 1.15 1 1.16 2.86
Chemotaxis G1p2 Interferon, alpha-inducible protein Mm.4950 24.58 35.12 21.39 27.01 14.17 1.63 1.57 10.47
Antiviral Mm.24045 Viral hemorrhagic septicemia virus (VHSV)
induced gene 1
Mm.24045 4.36 18.93 5.13 5.53 2.1 1.33 1.3 4.69
(continued on next page)
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Table 2B (continued)
Classification Function Gene Description UniGene Fold change in gene expression induced by each WNV
strain in infected mice relative to mock-infected mice
Average fold
change induced
by highly
vs. less
neuroinvasive
strains
SPU
116/89
H 442 NY
385/99
NY
2001Hu
AN
4766
AR
381/00
MRM
16
IFN responsive protein Ifrg28 28 kDa interferon alpha responsive protein Mm.180157 8.85 7.69 4.87 5.99 3.37 1.53 2.03 3.63
IFN responsive protein 2010008K16Rik Ifi35 Mm.45558 2.18 3.44 1.69 2.41 1.4 1.02 1.16 2.01
Transcription regulation Ifi204 Interferon activated gene 204 Mm.212870 4.07 3.63 2.71 2.4 2.27 1.06 0.92 2.49
Transcription regulation Sp100 Nuclear antigen Sp100 Mm.290906 2.27 3.57 1.62 1.92 1.05 0.72 0.76 2.45
Transmembrane Fragilis Interferon induced transmembrane protein
3 (Ifitm3), mRNA
Mm.141021 2.84 3.79 2.88 2.38 2.5 0.87 0.84 2.43
Antiviral Oasl1 2V–5V oligoadenylate synthetase-like 1 Mm.95479 4.66 3.39 4.93 4.08 2.43 1.92 0.67 3.2
Antiviral Oas1g 2V–5V oligoadenylate synthetase 1G Mm.260702 12.11 12.42 7.49 7.56 3.35 0.74 0.93 7.07
Antiviral Oasl2 2V–5V oligoadenylate synthetase-like 2 Mm.228363 4.49 3.17 2.98 4.18 0.98 1.44 0.81 3.38
Antiviral Mx2 Myxovirus (influenza virus) resistance 2 Mm.14157 2.61 2.07 4 3.07 2.43 1.39 0.92 2.32
Antiviral Mx1 Myxovirus (influenza virus) resistance 1 Mm.33996 2.11 1.96 1.74 2.41 1.03 1.04 0.58 2.19
Antiviral 2310061N23Rik RIKEN cDNA 2310061N23 gene,
interferon stimulated gene 12
Mm.271275 4.16 7.34 2.72 3.7 2.17 2.29 1.45 2.44
Ifit2 Interferon-induced
protein with
tetratricopeptide
repeats 2
Mm.2036 4.94 4.19 4.16 2.98 2.39 1.34 0.75 3.1
IFN inducible, virus
resistance, apoptosis
inhibitor
Igtp Interferon gamma induced GTPase Mm.33902 7.42 8.27 4.92 9.57 3.51 0.68 1.79 5.13
Antiviral 2310061N23Rik RIKEN cDNA 2310061N23 gene, interferon
stimulated gene 12
Mm.271275 4.16 7.34 2.72 3.7 2.17 2.29 1.45 2.44
D12Ertd647e DNA segment, Chr 12, ERATO Doi 647,
expressed
Mm.2121 5.75 6.99 7.2 7.05 6.18 1.09 1.47 3.73
Ifi1 Interferon inducible protein 1 Mm.29938 6.88 7.31 6.53 6.37 5.06 1.5 3.13 2.95
Hematopoietic
cell surface
molecule
and ligands
Th1 response Ly6c Lymphocyte antigen 6 complex, locus C Mm.326879 6.55 14.5 5.14 4.94 2.84 1.14 2.19 4.18
Ms4a6b Membrane-spanning 4-domains, subfamily A,
member 6B
Mm.278844 3.79 6.02 2.95 2.68 2.09 0.8 0.92 3.06
Inflammatory response,
TNF-alpha induced
CD47 CD47 antigen (Rh-related antigen,
integrin-associated signal transducer)
Mm.31752 1.52 1.66 1.49 1.41 1.25 0.93 1.05 1.43
Inflammatory response,
TNF-alpha induced
CD47 CD47 antigen (Rh-related antigen,
integrin-associated signal transducer)
Mm.299474 1.72 2.69 1.19 1.68 0.94 0.67 0.9 1.96
Ly6e Lymphocyte antigen 6 complex, locus E Mm.788 4.86 5.52 4.43 4.72 3.89 1.06 2.6 2.73
Ppicap Peptidylprolyl isomerase C-associated protein Mm.3152 4.79 4.1 3.84 4.64 2.69 1.49 1.39 2.8
Inflammatory response,
mast cell surface
glycoprotein
Gp49a Glycoprotein 49 A Mm.34408 2.64 2.67 1.75 2.87 1.74 1.43 0.83 1.94
Ly6f Lymphocyte antigen 6 complex, locus F Mm.57179 12.33 17.26 9.36 9.5 5.99 0.8 1.6 6.86
Ly6a Lymphocyte antigen 6 complex, locus A Mm.263124 13.25 18.82 8.88 10.85 5.54 1.01 1.7 6.89
GTPase activator,
hematopoietic cell
development
Arhgdib Rho, GDP dissociation inhibitor (GDI) beta Mm.2241 1.71 3.47 1.39 1.23 0.95 0.71 0.74 1.99
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Cytoskeleton Tmsb4x Thymosin, beta 4, x chromosome Mm.142729 2.24 2.59 1.35 1.79 1.17 0.61 0.77 2.19
Cytokine Pro-inflammatory IL6 Interleukin 6 Mm.1019 1.8 2.27 1.83 2.11 1.24 0.94 0.96 1.93
Chemokine Chemokine,
Th1 response
CCL2 Chemokine (C–C motif) ligand 2 Mm.290320 4.2 4.38 2.11 3.51 1.45 1.4 1.7 2.52
Chemokine,
Th1 response
CXCLl9 Chemokine (C–X–C motif) ligand 9 Mm.766 4.08 2.84 1.85 2.25 1.92 0.88 1.35 2.15
Cell growth and/or
maintenance
Ogfr Opioid growth factor receptor Mm.250418 2.41 2.85 2.22 2.42 1.67 1.41 1.12 1.9
Cell cycle Mki67 Antigen identified by monoclonal antibody Ki 67 Mm.4078 2.53 6.65 1.02 1.74 0.74 0.91 0.76 2.56
Cell adhesion,
negative
regulator
Cml1 Camello-like 1 Mm.13036 0.3 0.38 0.49 0.58 0.73 0.85 0.85 0.5
Apoptosis MHC class I Gzma Granzyme A Mm.15510 2.91 5.57 2.15 2.09 1.8 1.68 1.02 2.1
Apoptosis inhibitor,
response to
hepatic infection
Igfbp1 Insulin-like growth factor binding protein 1 Mm.21300 19.28 12.2 1.77 3.18 3.3 0.67 0.65 5.08
9130009C22Rik RIKEN cDNA 9130009C22 gene Mm.136224 3.65 4.61 2.89 3.88 1.99 0.63 0.98 3.32
Scotin Scotin gene Mm.196533 6.02 5.27 3.7 4.93 2.16 1.77 1.23 3.22
Antimicrobial
peptide
Leap2 Liver-expressed antimicrobial peptide 2 (Leap2),
mRNA
Mm.24283 0.41 0.46 0.85 0.67 1.02 1.29 0.93 0.54
Antigen
presentation
MHC class I Arts1 Type 1 tumour necrosis factor receptor shedding
aminopeptidase regulator
Mm.83526 2.24 2.06 1.51 1.85 1.1 0.92 1.09 1.83
MHC class I H2-Q1 Histocompatibility 2, Q region locus 1 Mm.290957 2.35 2.74 2.36 2.11 1.79 0.81 1.02 2.08
MHC class I H2-Q7 Histocompatibility 2, Q region locus 7 Mm.34421 1.97 3.41 1.82 1.66 1.68 0.9 0.86 1.9
MHC class I Tap1 Transporter 1, ATP-binding cassette,
sub-family B (MDR/TAP)
Mm.207996 4.85 4.1 2.23 3.55 1.81 1.63 1.3 2.36
MHC class I Tapbp TAP binding protein Mm.154457 2.21 2.51 1.95 1.89 1.38 1 1.29 1.84
DC Plac8 Placenta-specific 8 Mm.34609 4.98 12.98 3.08 4.4 2.44 1.31 1.88 3.32
Acute phase
response
Th1/2 regulator,
prevents liver fibrosis
Hp Haptoglobin Mm.26730 2.89 3.04 1.73 1.47 1.24 0.77 0.96 2.17
Prevents liver fibrosis Hpxn Hemopexin Mm.3485 3.4 2.44 1.71 1.32 1.13 1.06 0.97 1.97
Unknown
function
Mus musculus adult male hippocampus cDNA,
RIKEN full-length enriched library,
clone:2900034J12, full
18.79 35.5 24.52 25.11 11 2.09 1.69 9.86
Mus musculus adult male kidney cDNA, RIKEN
full-length enriched library, clone:0610010O05
3.96 4.4 3.82 4.53 3.13 0.86 1.03 3.08
2310040A07Rik RIKEN cDNA 2310040A07 gene Mm.34074 0.45 0.42 0.58 0.52 0.87 1.24 0.95 0.49
A430056A10Rik RIKEN cDNA A430056A10 gene Mm.30756 7.53 10.85 6.44 6.43 2.92 1.08 0.61 5.75
BC023105 cDNA sequence BC023105 Mm.329462 10.95 5.96 5.49 12.76 7.63 1.32 2.2 3.49
Galnt11 UDP-N-acetyl-alpha-D-galactosamine:
polypeptide N-acetylgalactosaminyltransferase 11
Mm.246718 1 1.7 1.81 2 0.78 0.71 1 2.3
Grwd1 Glutamate-rich WD repeat containing 1 Mm.349739 3.5 2.38 1.67 2.06 1.18 0.76 1 2.31
Lmcd1 LIM and cysteine-rich domains 1 Mm.234441 2.7 1.86 1.75 1.88 1.41 1.01 0.83 1.88
Fdps Farnesyl diphosphate synthetase Mm.39472 0.32 0.54 0.92 0.86 1.31 1.65 2.37 0.42
GTP binding 5830443L24Rik RIKEN cDNA 5830443L24 gene Mm.354723 9.74 9.3 4.21 6.71 2.76 0.69 1.05 5.83
9830147J24Rik RIKEN cDNA 9830147J24 gene Mm.45740 6.86 7.2 3.56 5.89 1.87 0.76 1.5 4.68
The fold change induced by infection with each WNV strain relative to mock infection is shown in a separate column, and the average change induced by the 4 more highly relative to the 3 less
neuroinvasive strains is shown in the last column.
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Table 2C
Genes with 1.62 or 1/1.62-fold change in expression on average in spleens of mice following subcutaneous infection with 4 highly neuroinvasive strains of WNV relative to 3 less neuroinvasive strains
Classification Function Gene Description UniGene Fold change in gene expression induced by each WNV
strain in infected mice relative to mock-infected mice
Average fold
change induced
by highly
vs. less
neuroinvasive
strains
SPU
116/89
H 442 NY
385/99
NY
2001Hu
AN
4766
AR
381/00
MRM
16
Transcription
regulation
Transcription regulation Trim30 Tripartite motif protein 30 Mm.33905 8.35 6.94 7.11 6.43 4.36 1.64 1.41 3.95
Transcription regulation Kcnq1 Tripartite motif protein 25 Mm.4973 3.46 2.19 2.37 1.9 1.74 1 0.93 1.96
IFN regulator Irf1 Interferon regulatory factor 1 Mm.1246 2.09 2.19 1.54 1.71 1.41 1.18 1 1.7
IFN regulator Irf7 Interferon regulatory factor 7 Mm.3233 12.33 4.9 13.65 12.43 7.27 2.31 1.67 4.03
Signal
transduction,
immune
response
Fln29 FLN29 gene product Mm.20488 3.3 2.07 2.49 2.41 1.22 1.48 1.01 2.18
Protein
degradation
Antigen presentation Psmb9 Proteosome (prosome, macropain) subunit,
beta type 9 (large multifunctional protease 2)
Mm.16251 2.61 2.53 2.27 1.83 1.78 1.27 0.82 1.94
MHC class I
presentation
Psmb8 Proteosome (prosome, macropain) subunit,
beta type 8 (large multifunctional protease 7)
Mm.13913 2.73 2.47 2.58 2.21 1.76 1.19 1.31 1.9
Fbxl6 F-box and leucine-rich repeat protein 6 Mm.27655 3.72 2.37 3.16 3.52 2.77 1.26 1.5 1.99
Zfp313 Zinc finger protein 313 Mm.22225 3.51 2.59 3.31 3.72 2.38 1.92 0.94 2.09
Miscellaneous Saa4 Carbonic anhydrase 1 Mm.3471 2.13 1.59 2.06 1.15 0.59 1 0.39 2.49
Hematopoietic cell
surface
molecule and
ligands
Ion transport Ly6f Potassium voltage-gated channel, subfamily Q,
member 1
Mm.5177 8.31 8.64 7.38 8.59 5.25 1.7 2.09 3.63
IFN-inducible
proteins
IFN-gamma induced Samhd1 SAM domain and HD domain, 1 Mm.196457 4.1 2.13 2.42 3.2 2.14 1.46 1.18 2.01
IFN responsive Tor3a Torsin family 3, member A Mm.206737 4.45 3.07 2.37 2.7 2.32 1 1.04 2.29
IFN regulator Usp18 Ubiquitin specific protease 18 Mm.27498 5.5 4.1 5.98 4.8 2.93 1.43 0.94 3.48
IFN regulator Socs1 Suppressor of cytokine signaling 1 Mm.130 2.63 2.22 2.33 2.23 1.62 1 1.05 1.97
IFN induced
transmembrane protein
Ifitm3 RIKEN cDNA 1110004C05 gene Mm.141021 4.71 5.26 4.37 4.31 3.04 0.85 1.12 3.46
GTPase Tgtp T-cell specific GTPase Mm.15793 16.09 12.14 15.01 14.17 8.47 1.02 2.21 6.26
DNA binding Zbp1 Z-DNA binding protein 1 Mm.116687 5.19 5.46 4.76 3.62 2.28 1.43 1.85 2.96
Antiviral Oas1a 2V–5V oligoadenylate synthetase 1G Mm.260702 18.82 20.03 12.77 12.39 9.88 1.42 2.63 6.14
Antiviral Oas1b 2V–5V oligoadenylate synthetase 1B Mm.233471 4.6 3.85 3.57 4.41 2.97 1 1.01 2.69
Antiviral Oasl1 2V–5V oligoadenylate synthetase Mm.95479 6.41 8.4 8.41 7.14 5.18 1.78 1.17 3.75
Antiviral Oasl2 2V–5V oligoadenylate synthetase-like 2 Mm.228363 4.88 3.04 3.21 5.49 2.12 1.36 0.44 3.5
Antiviral Mx1 Myxovirus (influenza virus) resistance 1 Mm.33996 3.16 2.73 3.34 3.44 1.85 1.74 0.76 2.38
Antiviral Mx2 Myxovirus (influenza virus) resistance 2 Mm.14157 3.33 2.87 2.65 2.48 1.76 1 1.01 2.21
Antiviral 2310061N23Rik RIKEN cDNA 2310061N23 gene Mm.271275 5.86 4.04 5.12 5.59 4.38 1.4 1.16 3.01
Antiviral 9130002C22Rik 2V–5V oligoadenylate synthetase-like 1 Mm.95479 12.18 4.84 6.6 9.94 5.26 1 1.5 3.98
IFN induced G1p2 RIKEN cDNA 2010008K16 gene Mm.45558 40.45 21.06 27.35 21.19 15.63 2.01 2.85 7.66
IFN induced Ifit2 Interferon-induced protein with tetratricopeptide
repeats 2
Mm.2036 2.89 3.67 3.14 3.11 2.32 0.93 0.81 2.76
IFN induced Trim25 Interferon, alpha-inducible protein Mm.4950 2.92 2.55 2 2.92 1.12 1 1.29 2.21
Transcription regulator Ifi16 Interferon activated gene 204 Mm.212870 6.15 5.53 4.89 4.35 4.55 1.21 1.39 2.95
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Ifi35 RIKEN cDNA 2310042L19 gene Mm.45163 2.91 2.12 2.32 3.09 2.16 1.33 0.97 1.92
Anti-intracellular
pathogen
Ifi1 Interferon inducible protein 1 Mm.29938 5.84 3.96 4.51 4.4 2.97 0.81 1.88 2.94
Hematopoietic cell
surface
molecule and
ligands
Ion transport Ly6f Potassium voltage-gated channel, subfamily Q,
member 1
Mm.5177 8.31 8.64 7.38 8.59 5.25 1.7 2.09 3.63
Gp49b Glycoprotein 49 B Mm.34408 2.21 2.41 2.14 2 1.27 1.05 0.78 2.13
Ly6c Lymphocyte antigen 6 complex, locus C Mm.1583 9.47 7.82 6.18 6.46 4.35 1 1.69 4.28
Ly6a Lymphocyte antigen 6 complex, locus A Mm.263124 7.5 6.55 5.25 4.81 3.21 1.25 1.05 4.09
Gp49a Glycoprotein 49 A Mm.196617 3.01 2.74 1.77 2.24 1.5 1 0.86 2.18
Growth factor
receptor
Ogfr Opioid growth factor receptor Mm.250418 1.95 2.03 1.46 2.52 1.91 0.54 0.81 1.98
Extracellular
matrix and cell
adhesion
molecules
Lgals9 Lectin, galactose binding, soluble 9 Mm.18087 3.71 2.42 3.64 3.28 2.23 0.62 1.01 2.71
Lgals3bp Peptidylprolyl isomerase C-associated protein;
Lgals3bp: lectin, galactoside-binding, soluble,
3 binding protein
Mm.3152 4.01 3.31 3.67 5.14 2.74 1.36 1.37 2.6
DNA binding Enzymatic D11Lgp2e DNA segment, Chr 11, Lothar Hennighausen 2,
expressed
Mm.271830 5.42 4.38 4.56 5.74 3.67 1.92 1.13 2.7
Inflammation Adar Adenosine deaminase, RNA-specific Mm.253961 2.81 2.55 1.95 3.04 1.66 0.94 1.12 2.21
IFN induced Sp100 Nuclear antigen Sp100 Mm.262144 5.28 3.28 6.55 7.18 4.03 1 1.6 3.06
Gbp2 Guanylate nucleotide binding protein 2 Mm.24038 2.65 4.04 1.83 1.66 1.82 0.99 1.24 2
IFN induced Gbp3 Guanylate nucleotide binding protein 3 Mm.1909 3.8 5.57 2.66 2.62 2.42 1.43 1.12 2.6
Chemokine Igtp Chemokine (C–X–C motif) ligand 9 Mm.766 3.13 3.5 2.8 3.94 1.76 1.47 1.51 2.41
Cxcl9 CXCL9-chemokine (C–X–C motif) ligand Mm.766 1.84 1.84 1.5 1.54 1.42 0.97 0.81 1.63
Carbohydrate
metabolism
Fbp2 Fructose bisphosphatase 2 Mm.2974 5.16 3.98 2.98 3.56 2.6 1.66 1.54 2.23
Apoptosis Gzmb Granzyme B Mm.14874 5.92 5.49 4.4 3.64 2.34 1 1.09 3.54
Gzma Granzyme A Mm.15510 8.11 5.7 9.11 8.3 6.99 1.75 1.39 3.36
Daxx Fas death domain-associated protein Mm.28118 2.43 2.68 2.16 2.58 1.65 1 1.18 1.96
Antigen
presentation
MHC class I H2-Q1 Histocompatibility 2, Q region locus 1 Mm.290957 2.15 2.54 2.94 2.28 2.4 0.79 1.03 1.98
MHC class I H2-Q8 Histocompatibility 2, Q region locus 8 Mm.234168 3 4.06 3.03 2.88 2.2 0.86 1.09 2.66
MHC class I B2m Beta-2 microglobulin Mm.163 4.1 3.07 3.01 2.42 2.71 0.74 1.23 2.31
MHC I Tap1 Transporter 1, ATP-binding cassette, sub-family
B (MDR/TAP)
Mm.207996 2.72 2.76 1.85 2.4 2.09 1.22 0.94 1.91
MHC class I H2-Q1 Histocompatibility 2, Q region locus 1 Mm.98003 1 2.54 2.15 2.28 2.4 0.79 1.03 1.98
MHC class I Tapbp TAP binding protein Mm.273435 1.77 2.6 1.55 2.36 1.33 1.08 0.98 1.94
Acute phase
response
Saa4 Serum amyloid A 4 Mm.3489 7.49 3.91 3.91 6.6 3.43 1 1.44 2.83
Actin/cytoskeleton Plec1 Plectin 1 Mm.203873 2.81 2.38 2.45 2.8 2.33 1 1.04 1.88
Dbnl Drebrin-like Mm.27622 1.79 1.68 1.38 2.09 1.13 0.95 1.06 1.67
Unknown function BC013672 cDNA sequence BC013672 Mm.33332 7.64 3.99 5.17 5.92 3.47 1.52 1.17 3.07
Mus musculus adult male hippocampus cDNA,
RIKEN full-length enriched library,
clone:2900034J12, full
Mm 19.36 14.1 16.07 15.67 10.14 1.95 2.52 5.8
A430056A10Rik RIKEN cDNA A430056A10 gene Mm.30756 6.32 6.48 4.67 6.38 2.63 0.67 0.89 5.13
Serpina3g Serine (or cysteine) proteinase inhibitor,
clade A, member 3G
Mm.264709 11.01 5.05 3.84 3.33 2.71 1.24 1.65 3.21
5830458K16Rik RIKEN cDNA 5830458K16 gene Mm.180157 7.5 4.47 5.02 6.36 5.22 1.64 1.14 3.13
2510038N07Rik RIKEN cDNA 2510038N07 gene Mm.30552 5.95 2.89 3.23 4.5 2.85 1.03 1.16 2.67
(continued on next page)
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torsin protein, Tor3a, which increased an average of 4-fold
(Table 2A), is an ATP-dependent IFN responsive gene,
related to the AAA chaperone-like family of ATPases
thought to play a role in protein folding, and may have a
protective role in neurons against a variety of cellular insults
(Dron et al., 2002; Shashidharan et al., 2004).
A number of genes associated with apoptosis was
increased significantly in the brains of mice infected with
the highly neuroinvasive strains. Pdcd1lg1, with 6-fold
average increased expression (Table 2A), is a member of the
B7 gene family expressed by antigen-presenting cells
including human peripheral blood monocytes stimulated
with IFN-g, activated human and murine dendritic cells, and
non-lymphoid tissues. Pdcd1lg1 expression on non-lym-
phoid tissues may determine the extent of immune response
at sites of inflammation (Freeman et al., 2000). Expression
of Pdcd1lg1 on dendritic cells has been implicated in the
induction and maintenance of T-cell anergy (Selenko-
Gebauer et al., 2003). This suggests a possible immuno-
regulatory role for Pdcd1lg1 in WNV infection, in control-
ling the influx of cytotoxic lymphocytes (CTL) and
inflammatory cells.
Other pro-apoptotic genes with increased expression
include the Scotin and Daxx genes that induce apoptosis
in a caspase-dependent manner (Engelhardt et al., 2001), or
by acting as a Fas receptor (Li et al., 2000; Perlman et al.,
2001; Zhong et al., 2000). Finally, the glucocorticoid-
induced leucine zipper factor (Gilz) with 2-fold average
increase, protects T cells from the onset of apoptosis
(Asselin-Labat et al., 2004), and modulates T-cell activation
by inhibiting both T-cell receptor (TCR)-induced IL2 or IL2
receptor expression, and NF-kappa B activity (Perlman et
al., 2001).
Genes with increased expression in the livers of mice
infected with highly neuroinvasive WNV strains
Many of the same categories of genes as in the brain had
increased expression in the liver following infection with the
more highly neuroinvasive strains relative to the less
neuroinvasive strains, with the majority of genes falling
into the functional categories of defense response, response
to biological stimulus, immune response, and acute phase
response (predicted with EASE) (Table 2B).
Genes associated with IFN pathways which had
increased expression included the transcription factors
Irf1, Irf7, and Stat-1, which had average increases of 1.7
(Irf1)- to 4-fold (Irf7), and these have all been associated
with liver disease (Siebler et al., 2003; Streetz et al., 2001).
Protein degradation genes with increased expression
included those associated with MHC Class I and II antigen
presentation such as the Psmb8 and cathepsin S (Ctss) genes
(Table 2B), while the ubiquitin-specific protease Usp18,
which had a 4-fold increased gene expression, is a negative
regulator of IFN signaling through the Jak-Stat pathway
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protection against over stimulation of the IFN pathway by
highly neuroinvasive WNV infections.
As in the brain, various IFN-induced antiviral genes had
increased expression in the more highly neuroinvasive WNV
infections, including the Mx genes and members of the Oas
gene family, although the so-called flavivirus resistance
gene, Oas1b, was not involved. The gene belonging to this
group that showed the highest increase in expression, 17-
fold, was the T-cell-specific GTPase (Tgtp), which is
expressed exclusively in T cells and plays a role in T-cell
development and activation (Carlow et al., 1995).
The IFN-a inducible protein G1p2, with 10-fold
increased expression (Table 2B), is known to have chemo-
tactic activity towards neutrophils and activated neutrophils
to induce the release of eosinophil chemotactic factors
(Owhashi et al., 2003), which suggests a pro-inflammatory
response. Other antiviral proteins which had increased
expression in the liver included Vig1-pending (viral
hemorrhagic septicemia virus induced gene 1), and Igtp
(IFN-g-induced GTPase).
Acute phase and inflammatory response genes that had
increased expression included macrophage expressed gene 1
(Mpeg1), which contains a domain that may share distant
ancestry with perforin, a lytic protein found in CTL and
natural killer cells (Spilsbury et al., 1995), plus members of
the lipocalin family, including serum amyloid A2 (Saa2)
which has been implicated in several pathological con-
ditions including atherosclerosis and rheumatoid arthritis
(Meek et al., 1994; Wang et al., 2002a, 2002b).
The chemokines CCL2/MCP-1 and CXCL9/MIG were
expressed 2.5- and 2.1-fold higher on average in the more
highly neuroinvasive WNV-infected livers. CCL2 (chemo-
kine C–C motif ligand 2, or monocyte chemoattractant
protein-1) fulfills a novel anti-inflammatory role in T-cell-
mediated hepatitis by inhibiting CD3(+)NK1.1(+) T cell-
derived IL4 production through direct stimulation of its
specific receptor CCR2 (Ajuebor et al., 2003). CXCL9/
MIG (chemokine C–X–C motif ligand 9) has been shown
to function as a negative regulator of murine eosinophils in
the lungs, and inhibits a CCR3-mediated functional
response in eosinophils (Fulkerson et al., 2004). Peak
expression of CXCL9/MIG and CXCL10/IP-10 was shown
to occur 4 days before CD8+ T cells infiltrated the tissues
in rickettsial infections, suggesting a role during the early
immune response (Valbuena et al., 2003). Expression of
IL-6, which has been shown to play a protective role
following liver injury (Masubuchi et al., 2003), was
increased 2-fold in infections with the more highly
neuroinvasive WNV strains (Tables 2A, B, C). IL-6
together with IL-1 and TNF-alpha acts as an endogenous
pyrogen by causing fever following viral infections and
activates hepatocytes to synthesize acute phase proteins
which function as opsonins (Heinrich et al., 1990).
Evidence suggests that circulating IL-6 can activate CNS
mechanisms resulting in the development of the febrileresponse during disease (Cartmell et al., 2000). Upregula-
tion of IL6, CCL2/MCP-1, and CXCL9/MIG may thus be
protective against harmful WNV-induced inflammatory
response in the liver, but IL-6 may also have a pathogenic
role when secreted into the blood.
Various hematopoietic cell surface molecules had
increased expression, including some Ly6 (lymphocyte)
antigens, a group of molecules that are involved in signal
transduction and cell activation (Classon and Coverdale,
1994). Products of the Ly6a/e loci are associated with CD4+
T-helper cell proliferation in response to antigen (Henderson
et al., 2002).
Pro-apoptotic genes that had increased expression in the
livers of mice infected with the more highly neuroinvasive
strains included granzyme A (Gzma) and the Scotin gene.
However, the insulin-like growth factor binding protein 1
(Igfbp1), which functions as a critical hepatic survival factor
by reducing the level of pro-apoptotic signals (Leu et al.,
2003), had an average increased expression of 5-fold,
suggesting the occurrence of a protective response.
Genes with increased expression in spleens of mice infected
with highly neuroinvasive WNV strains
Most of the genes with increased expression in the spleen,
were the same as in the liver and brain, or covered the same
antiviral function groups (Tables 2A, B, C). A strong IFN-
pathway-related response included genes such as IFN
regulators Irf1, Irf7, and Socs1 (suppressor of cytokine
signaling 1), Oas and Mx1 antiviral proteins, protein
degradation and MHC Class I antigen presentation genes,
apoptosis genes Gzma and Gzmb, chemokine CXCL9/MIG,
and the hematopoietic cell surface molecules Ly6. The genes
with the highest increases were of unknown function, G1p2
with 8-fold increase, and 2900034J12Rik, 6-fold increase.
Substantial increases of Tgtp, 6-fold, and Oas1g, 6-fold,
implies the occurrence of a strong antiviral protective
response.
Cluster analysis of the original list of genes that were
differentially expressed in spleens in WNV infections
relative to mock infection, suggests that the same genes
had increased expression following infection with the
Ethiopian strain AN4766 as with the more highly neuro-
invasive strains, while the remaining 2 less neuroinvasive
strains, MRM16 and AR381/00, did not induce similar
increase in gene expression in the spleen (results not shown).
However, selection criteria were deliberately biased to
identify genes differentially expressed in infections with
more highly neuroinvasive WNV strains relative to less
neuroinvasive strains, and consequently some genes that had
increased expression in spleens by all or most strains of virus
were excluded from analysis, including, for instance, Oas3,
Vig1-pending, D11Lgp2e (DNA segment, Chr 11, Lothar
Hennighausen 2, expressed), Bagl-pending (B aggressive
lymphoma), 1300004C08Rik (RIKEN cDNA 1300004C08
gene), Igtp, Adcy3 (adenylate cyclase 3), and Stat-1.
Table 4
Quantitative real-time PCR ratio of the NS5 gene of each WNV strain
relative to the mouse housekeeping gene (PBGD) in each organ pool used
in the microarray experiments
WNV strain WNV-NS5/PBGD
Brain Liver Spleen
SPU116/89 80.2 0.0010 0.0378
H442 62.74 0.17 0.0084
NY385/99 22.56 0.0036 0.0811
NY2001Hu 53.29 0.0012 0.0028
AN4766 0.0179 Neg 0.0211
AR381/00 0.0003 0.0001 0.0654
MRM16 ND* 0.0001 0.0113
* ND = not done, insufficient RNA available.
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RT-PCR
The results obtained by microarray analysis for 5 genes,
CXCL11/I-TAC, Stat-1, Apod, Irf1, and Scotin gene, that
were found to have significantly increased expression in the
brains of mice infected with the more highly neuroinvasive
WNV strains, were checked by kinetic quantification in RT-
PCR relative to the mouse PBGD housekeeping gene, and
the results are presented in Table 3. The values represent
the average of 3 repetitions of the quantitative PCR and are
expressed relative to the mock infection. The results of
melting curve analyses confirmed the specificity of RT-PCR
products (data not shown). Although absolute values are
not identical due to intrinsic differences between the
techniques, the RT-PCR results reveal the same relative
regulation of transcription as the microarray data, and
confirm that expression of the selected genes was signifi-
cantly increased in response to infection with the more
highly neuroinvasive WNV strains. DNA microarrays are
thought to be less sensitive than quantitative PCR and to
suppress the actual differences in gene expression. Quanti-
tative PCR is used most frequently to confirm microarray
results and although quantitative differences are found
between array and RT-PCR data, comparative results
confirmed the qualitative accuracy of the microarray results
(reviewed by Chuaqui et al., 2002).
WNV replication in mouse brain, liver, and spleen
The levels of expression of the WNV NS5 gene in the
organs of mice relative to the housekeeping gene PBGD, are
shown in Table 4. The 4 strains that were identified as moreTable 3
Confirmation by real-time quantitative RT-PCR of the results obtained by
DNA microarray analysis for relative expression of 5 selected genes
induced in brains of mice by infection with 7 strains of WNV
Gene SPU116/
89
H442 NY385/
99
NY2001Hu AN4766 AR381/
00
MRM16
Microarray results
Cxcl11 29.45 19.70 4.11 7.26 1.34 1.43 1.00
Stat-1 12.82 10.27 6.32 9.45 2.95 0.90 1.05
Apod 6.02 3.71 3.12 3.27 0.55 1.09 1.39
Irf1 6.77 6.41 2.23 3.63 1.35 0.95 1.96
Scotin 3.16 3.18 1.77 2.00 1.55 0.77 1.00
RT-PCR resultsa
Cxcl11 336.96 159.93 18.76 65.83 1.47 0.36 ND*
Stat-1 51.54 127.73 53.69 156.79 23.82 1.63 ND
Apod 20.00 4.67 4.15 12.96 1.45 1.43 ND
Irf1 8.95 70.17 39.43 68.41 2.95 0.85 ND
Scotin 6.11 20.54 6.02 6.01 3.69 1.10 ND
The actual fold change in gene expression relative to mock-infected mice is
shown for each WNV strain.
a The RT-PCR results are the average of 3 quantitative PCR repetitions
with the same RNA as used for the microarrays.
* ND = not done, insufficient RNA available.highly neuroinvasive, NY385/99, NY2001Hu, SPU116/89,
and H442, were present at much higher levels in brain than
the less neuroinvasive strains (Table 4). Strain AN4766
could not be amplified in the liver, but otherwise all strains
could be detected in the spleen and liver at much lower
levels than in brain.Discussion
The 7 WNV strains included in the present study were
selected to represent a range of pathogenic phenotypes.
Among lineage 1 isolates, NY385/99 and NY2001Hu were
associated with fatal bird and human encephalitis in the
USA, Ethiopian strain AN4766 was isolated from an
ostensibly healthy bird in a survey, while MRM16 was
isolated from mosquitoes in Australia (Beasley et al., 2002;
Huang et al., 2002). Two of the lineage 2 human isolates
from South Africa, H442 and AR381/00, were associated
with benign febrile disease while the third, SPU116/89, was
obtained from a patient with fatal hepatitis (Burt et al.,
2002). Five of the above isolates were included in a
pathogenicity study by Beasley et al. (2002) in which they
defined neuroinvasiveness in terms of the dose of virus
required for each WNV strain to produce fatal infection
following peripheral inoculation in mice. They expressed
the LD50 values determined for each strain as plaque
forming units (PFU) of virus, and selected an arbitrary
LD50 cutoff value equivalent to 50 PFU of virus to
distinguish isolates that were more highly from those that
were less neuroinvasive, and established that pathogenic
phenotype of WNV varies with genotype, and not lineage,
source of isolate, geographic distribution, passage level, or
year of isolation.
Differences in neuroinvasiveness of WNV strains ob-
served in the present study were marked between strains at
the extremes of the spectrum, but minimal and therefore not
necessarily reproducible between strains in mid range (Table
1). Nevertheless, our findings on relative neuroinvasiveness
coincide with those of Beasley et al. (2002) for the 5 isolates
included in both studies, and the levels of virus replication
detected by RT-PCR in brain tissue confirm that we
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invasive under the conditions of the present investigation
(Table 3). Moreover, the gene expression levels we detected
in brain tended to be consistently higher in mice infected
with the 4 WNV strains rated as more highly neuroinvasive,
irrespective of lineage (Tables 2A, B, C). This confirms that
the ability of the WNV strain to enter the brain and replicate
to high levels largely determines its virulence, although it is
the increased expression of protective and pathological host
genes that most likely determines the outcome of the
infection. Essentially the same genes tended to have
increased expression in each instance, although not neces-
sarily to the same extent with each of the WNV strains.
Despite the occurrence of much lower levels of WNV
RNA in the liver and spleen than in the brain, all of the
neuroinvasive strains nevertheless induced increased host
gene expression in these organs. Although it is possible that
the immune response may already have cleared the virus
from these organs by the time we measured gene expression,
the higher viral burden in the brain associated with the
neuroinvasive strains may also lead to a more significant
induction of acute phase reactants by the liver, while
circulating antigen-presenting cells from the brain may
activate lymphocytes in the spleen, which is a major
peripheral lymphoid organ.
The majority of the genes found to have increased
expression in brain following infection with the more
highly neuroinvasive strains of WNV, belong to functional
groups already shown to be elevated by other viruses,
suggesting that common cell pathways are activated during
neurotropic viral infection of the CNS, and the gene
products may be involved in protective roles but could also
contribute to the pathogenesis of the disease (Johnston et
al., 2001; Saha and Rangarajan, 2003; Wang et al., 2002a,
2002b). This group includes the IFN-inducible transcrip-
tion factor Stat-1, the pro-apoptotic Irf1 which regulates
transcription of many IFN-inducible gene products,
immune cell activation markers, and chemokines. Stat-1
is thought to play a role in protection against IFN-a
mediated injury to the CNS, and has increased expression
in response to infection by several viruses, including
Japanese encephalitis virus (JEV) and rabies (Saha and
Rangarajan, 2003, Wang et al., 2002a, 2002b). Stat-1 is
also upregulated in the brains of rhesus macaques during
neuroAIDS following simian immunodeficiency virus
(SIV) infection (Roberts et al., 2003). Fredericksen et al.
(2004) found increased expression of IRF-3 following
WNV infection of human embryonic kidney cells.
Although IRF-3 was not differentially expressed between
highly and less neuroinvasive WNV-infected mice, IRF-1
was significantly higher in the brain and both IRF-1 and 7
were increased in the liver and spleen of mice infected
with the more highly neuroinvasive WNV strains. IRF-7
and IRF-3 are both activated in the presence of double-
stranded RNA following virus infection and all 3 of these
genes function as regulators of the IFN-a/h gene promoterand the IFN-a/h responsive genes to create an antiviral
state (Samuel, 2001).
The increased expression of T-cell activation markers and
chemokines, such as CXCL11/I-TAC, suggests that T cells
may play an important role in the host response to highly
neuroinvasive WNV infection. It has been shown that CD8+
but not CD4+ T cells constitute the main inflammatory cells
infiltrated into the brains of mice infected with WNV, and
that these cells mediate the occurrence of immunopathology
and recovery in encephalitis (Wang et al., 2003). Infiltration
of inflammatory cytokines and T cells into the brain has been
associated with neuronal injury and paralysis following
rabies virus infection (Sugamata et al., 1992), and fatal
encephalitis following neurovirulent Sindbis virus infection
(Rowell and Griffin, 2002). T cells may contribute to the
occurrence of fatal encephalomyelitis through the production
of IFN-g in Sindbis virus infection since it was observed that
mice lacking either CD4+ or CD8+ T cells had reduced
mortality, while mice lacking IFN-g were completely
protected (Rowell and Griffin, 2002). CXCL11 is also
chemotactive for NK cells although evidence suggest that
flaviviruses and in particular WNV have developed a
mechanism to evade NK cell responses through an augmen-
tation of cell surface class I MHC expression (Momburg et
al., 2001). It has been suggested that flaviviruses may
overcome NK cell-mediated lysis at the expense of increased
MHC class I expression and later recognition by virus-
specific CTL (Chambers and Diamond, 2003).
Comparison of specific cytokines induced following
infection with lethal and non-lethal WNV strains in mouse
brains confirmed the upregulation of the T-cell chemotactic
CC chemokines: CCL5/RANTES, CCL3/MIP-1 alpha,
CCL4/MIP-1 beta, and CXCL10/IP-10 were increased in
the brains of mice infected with the virulent NY strain,
while B lymphocyte chemoattractant (CXCL13/BLC)
mRNA was not detected in either group of mice, and B
cell- and monocyte-activating chemokine (CXCL14/
BMAC) mRNA was upregulated at a late stage of infection
with the non-lethal Eg101 strain (Shirato et al., 2004). The
difference in RNA levels as measured by quantitative PCR
between these genes in infections with lethal and non-lethal
strains were found to be much higher at 7 days pi than at 3
days pi. The fact that we did not detect differential
expression of the same genes may be because we measured
expression at day 5 pi, or possibly because DNA micro-
arrays are less sensitive than quantitative PCR. Never-
theless, detection of increased expression of CXCL11/
I-TAC in our study confirms the importance of T-cell
chemotactic chemokines in pathogenic WNV infection.
As in infection with neurovirulent Sindbis virus (Johnston
et al., 2001), no increases in expression of IFN-a and -hwere
observed in the brains of mice infected with the more highly
neuroinvasiveWNV strains, despite the induction of the IFN-
a and -h transcription activators (Irf1), the signaling
molecule Stat-1, and various IFN-inducible genes. It was
suggested in the Sindbis study that the IFN response was
M. Venter et al. / Virology 342 (2005) 119–140134missed because it occurs early in CNS infection (Johnston et
al., 2001). Nevertheless, activation of IFN-pathway-related
genes identified in the present and in the Sindbis investigation
may represent mediation of IFN-a and -h antiviral host
response to neurovirulent virus infection.
The Oas1b protein has been described as a flavivirus
resistance factor, and Oasl1 as a WNV-resistance factor in
wild mice because a truncated version of the protein is
expressed in laboratory mice which are susceptible to
infection (Lucas et al., 2003; Mashimo et al., 2002; Samuel,
2002). However, recent studies with another flavivirus,
Murray Valley encephalitis virus (MVEV), indicated that
lower virus titers, milder inflammation, lower counts of
infiltrating cells, and lower IFN I/II and IFN-a gene
induction occurred in the brains of resistant than in
susceptible mice. In contrast, transcripts of several genes
belonging to the Oas family implicated in the IFN I-
inducible Oas/RNAse L antiviral pathway showed similar
induction in both strains of mice, suggesting only a minor
contribution of this pathway in resistance to MVEV
infection (Silvia et al., 2004). In the present study, there
was increased expression of various other members of the
Oas family in the brains of mice infected with the highly
neuroinvasive WNV strains, and there were also indications
of infiltrating T cells, increased IFN gene induction, and
more intense viral replication (Tables 2A and 4). Although
Oas1b and Oasl1 genes are thought to be inactive in
laboratory mice, murine Oasl2 has been demonstrated to be
a functional 2V–5V oligoadenylate synthetase (Eskildsen et
al., 2003), while Oas1g (alias Oas1a) confers resistance to
encephalomyocarditis virus but not to vesicular stomatitis
virus replication in mice (Coccia et al., 1990). The ability of
these proteins to protect against WNV infection should
therefore also be assessed.
CNS-specific proteins implicated in the pathogenesis of
neurological disease and found to have increase expression
in mouse brains infected with highly neuroinvasive WNV
strains included the lipocalin Apod, which is associated with
brain injury and is also expressed in response to JEV, rabies,
SIV, and Sindbis virus infections (Johnston et al., 2002;
Saha and Rangarajan, 2003; Roberts et al., 2003), plus Gfap
which mediates the occurrence of gliosis. Glial scarring is
associated with the inability of neurons to regenerate axons,
leading to permanent functional disabilities in the injured
adult mammalian spinal cord (Menet et al., 2003). It is
known that WNV infection can cause paralysis by destroy-
ing motor neurons in the anterior horn of the spinal cord
(Leis et al., 2003) in association with a high degree of virus
replication plus leukocyte infiltration and degeneration, and
induction of apoptotic mechanisms (Shrestha et al., 2003).
Infection of cultured mouse astrocytes with a neurovirulent
strain of Sindbis virus also induces a marked increase in the
expression of Gfap, whereas a non-neurovirulent strain does
not (Brodie et al., 1997).
WNV-induced apoptosis has been demonstrated in an
embryonic stem cell derived tissue culture model, andsuggests a potential mechanism for viral and immune-
mediated neuronal injury following WNV infection (Shres-
tha et al., 2003). Pro-apoptotic genes found to have
increased expression in the brains of mice infected with
the more highly neurovirulent WNV strains, include Scotin
and Daxx, plus Pdcd1lg1 which may lead to the inhibition
of T-cell receptor-mediated lymphocyte proliferation and
cytokine secretion. This in turn may determine the extent of
T-cell activation and the threshold between tolerance and
autoimmunity (Freeman et al., 2000). Pdcd1 and Pdcd1lg1
expression has been demonstrated in infiltrating inflamma-
tory cells in the brains of mice with experimental auto-
immune encephalomyelitis (Liang et al., 2003). Experi-
ments have shown that although the Pdcd1/Pdcd1lg1
inhibitory pathway affects both CD4(+) and CD8(+) T
cells, it may be overcome by addition of IL2, suggesting that
CD8(+) T cells may be more sensitive to modulation
because of their intrinsic inability to produce significant
levels of IL2 (Carter et al., 2002). This suggests a possible
immunoregulatory role for Pdcd1lg in WNV infection in
controlling the influx of CTL and inflammatory cells.
In contrast, the Glz factor may protect T cells from the
onset of apoptosis and modulate T-cell activation (Asselin-
Labat et al., 2004; Perlman et al., 2001). Persistent viral
infections of the CNS have been related to immune response
factors and to apoptotic modulators affecting the ability of
neurons to survive viral infection. Thus, upregulation of the
anti-apoptotic gene peripheral benzodiazepine receptor
(PBR) decreased neuronal apoptosis and protected 1-day-
old mice against fatal Sindbis virus infection without
inhibiting virus replication (Johnston et al., 2001). The
precise role of Glz or other apoptotic modulators in WNV
infections remains to be determined. However, some
evidence for the establishment of viral latency in T-
lymphocytes has been demonstrated in JEV infections of
mice (Mathur et al., 1989), and prolonged IgM antibody
production has been reported in a small number of WNV-
infected individuals (Roehrig et al., 2003) which may
suggest low levels of chronic persistent infection in some
cases.
Koh and Ng (2005) used microarray analysis to identify
genes potentially associated with pathogenesis following
WNV infection of human glioblastoma cells. Many of the
identified genes correlated well with our study, including a
number of interferon-induced proteins and cytokines. They
also identified apoptosis-related proteins although not the
same ones as in our study. However, none of the tran-
scription factors and CNS-specific proteins identified in our
study was upregulated in the brain cell cultures they used.
The unbiased examination of brain RNA from animals with
CNS disease may allow the identification of gene transcripts
found in infiltrating and activated immune cells as well as
other cell types in the affected brains, thus facilitating
identification of pathogenic gene products and molecular
pathways of disease. This was reflected in a microarray
analysis of the brains of rhesus macaques with SIV
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parallel findings with our study, including increased
expression of the interferon-inducible genes Ifi1, Ifi2,
Ifitm3, Isg15 alias G1p2, and Oas, CNS-specific genes
Apod and Gfap, lysosomal protein cathepsin, proteosome
psmb8l and Stat1 (Roberts et al., 2003). The investigators
showed that macrophage infiltration plays a major role in
SIV encephalitis, with limited lymphocyte infiltration seen
in lesions. In contrast, both macrophage and T-cell infiltra-
tion appear to play an important role in flavivirus
encephalitis (Chambers and Diamond, 2003).
Gene expression detected in the liver possibly reflects the
acute phase response induced by the infection of the brain,
although a few cases of WNV-associated hepatitis have been
reported (Burt et al., 2002), and one of the strains included
in the present study was isolated from the liver of a patient
who succumbed to hepatitis (SA116/89). Despite the small
number of WNV-associated hepatitis cases recorded in
humans, no infectious WNVand very low RNA levels could
be measured in the livers of wild type mice in the present
and in a previous study (Diamond et al., 2003). It was
shown that WNV replicates to high titer in the livers of mice
which lack B cells, and that antibody-mediated immunity
plays an important role in clearing virus from this organ
(Diamond et al., 2003). No further information is available
on genes that may be involved in protective or potentially
pathogenic responses in the liver.
We found that although much lower levels of WNV RNA
could be amplified from the livers and spleens of mice than
from brain, many of the same categories of genes had
increased expression in the liver as in brain. This could
indicate that the highly neuroinvasive strains induce more
intense viremia, and that a higher viral burden throughout
the body leads to more significant induction of acute phase
reactants which influence the pathogenic outcome of
infection. Although the mice did not serve as a model for
WNV-induced hepatitis, the liver gene expression which we
detected could represent additional pathogenic and protec-
tive mechanisms involved during WNV infection.
Various T-cell activation markers which could lead to the
occurrence of T-cell-mediated liver damage, were found to
have significantly increased expression in the livers of mice
infected with the more highly neuroinvasive WNV strains
(Table 2B). Inflammatory response genes which could
mediate hepatocyte damage were also found to have
increased expression in the liver. Although the occurrence
of IL6, CCL2/MCP-1, and CXCL9/MIG responses may
protect against the harmful inflammatory responses, IL-6 is
also associated with the induction of fever and activates
hepatocytes to produce acute phase proteins with potential
pathogenic roles (Cartmell et al., 2000; Heinrich et al.,
1990) and is associated with an unfavorable outcome
following yellow fever virus infection (ter Meulen et al.,
2004). Interleukin 6 has been proposed as the principal
endogenous circulating pyrogen during infection and
inflammation. Peripherally produced IL-6 can enter thebrain via an active transport mechanism to trigger CNS
factors producing febrile response during disease (Cartmell
et al., 2000).
We found that a strong IFN-pathway-related response
was evident in the liver, with increased expression of Irf1,
Irf7, and Stat-1 in infection with the more highly neuro-
invasive strains of WNV. IFN-g-dependent expression of
Irf1 and TNF-a-dependent activation of c-Jun N-terminal
kinase in liver cells has been correlated with hepatocyte
damage after administration of Con A (Streetz et al., 2001),
while Stat-1 plays a harmful role in Con A-mediated
hepatitis by activation of CD4(+) and NK T cells and
directly inducing hepatocyte death through upregulation of
pro-apoptotic Irf1 (Hong et al., 2002; Siebler et al., 2003).
Increased expression of the pro-apoptotic Gzma and Scotin
genes could help clear virus infection, but may also involve
liver injury. Markedly increased expression of Igfbp1, which
functions as a critical hepatic survival factor by reducing the
level of pro-apoptotic signals (Leu et al., 2003), was
observed in the infections with the more highly neuro-
invasive WNV strains, implying the occurrence of a
protective response.
Although highly neuroinvasive WNV strains were not
found at higher levels in spleens than the less neuroinvasive
strains, 81 genes in the spleens were significantly increased
following infection with these strains. Diamond et al. (2003)
demonstrated that following subcutaneous infection with a
WNV strain isolated in New York State, infectious virus
could be detected in the blood and spleen early in infection
(day 2) but rapidly decreased to undetectable levels by day
6, following the occurrence of a robust antibody response.
Since we measured gene expression on day 5, most viruses
may already have been cleared, implying that both highly
and less neuroinvasive strains were cleared equally well.
Unlike the brain, however, little correlation existed between
the level of viral RNA present at this stage in the spleen and
gene expression. Thus, the increased gene expression
observed in the spleen may either reflect the response to
earlier virus replication in the spleen, or cell signaling as a
result of higher virus replication in the brain. Genes with
significantly increased expression in spleen correlated well
with the genes with increased expression in the brain and
liver. The acute response in the brains of the infected mice
may be reflected by the response induced in peripheral
lymphoid organs. Antigens may be carried from sites with
high viral burden, such as the brain, and displayed by
specialized antigen-presenting cells to lymphocytes in the
spleen. Lymphocytes that are activated in the spleen may in
turn be recruited to sites where they are needed in the brain
and liver, with both protective and pathogenic implications.
Increased expression of the Socs1 gene, which is
associated with commitment of Th1 lineage CD4+ T cells
(Egwuagu et al., 2002), increased expression of many MHC
Class I antigen presentation molecules, and expression of
chemokines such as CXCL9/MIG, and Ly6 antigens,
suggests the occurrence of a strong CTL response in the
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T-lymphocytes in the spleen and their recruitment to liver
and brain could contribute to T-cell-mediated injury to both
organs. Furthermore, previous investigations have suggested
that although flavivirus infections generally elicit strong
immune responses, this does not always occur rapidly
enough to protect the host from developing encephalitis
(Brinton et al., 1998).
It has been suggested that there is a direct relationship
between systemic virus burden and viremia in flavivirus
infections, and that the potential of virus to generate viremia
correlates with neuroinvasion since this has been observed
to apply to most naturally acquired encephalitic infections
(Albrecht, 1968). Thus, a higher viral burden associated
with neuroinvasive strains may lead to a more potent acute
immune response. This may explain why the more highly
neuroinvasive WNV strains induced increased expression of
genes associated with the antiviral response in the brain,
liver, and spleen, relative to the less neurovirulent strains.
Recent investigations have shown that WNV infection leads
to a Toll-like receptor 3-dependent TNF-alpha response,
which is involved in brain penetration of the virus and
neuronal injury (Wang et al., 2004). TNF-alpha levels which
play an important role in altering the permeability of the
blood–brain barrier may thus be induced more by the highly
neuroinvasive strains early in infection which could allow
greater access to the central nervous system.
To conclude, we identified host genes that are differ-
entially expressed in the brains, livers, and spleens of mice
following infection with more highly relative to less
neuroinvasive strains of WNV, and these genes may help
explain pathogenic mechanisms which distinguish the
strains. Genes associated with the IFN pathway, T-cell
response, inflammation, and apoptosis may help control
viral infection, but could also contribute to the pathogenesis
of WNV resulting in encephalitis and in some instances
hepatitis, with potential implications for treatment of the
infection. CNS- and liver-specific genes that increase the
pathogenic potential of virus infection were also identified,
and these could prove to be additional therapeutic targets.Materials and methods
Viruses and propagation
Low passage freeze-dried mouse brain stocks of lineage
2 WNV isolates were obtained from the collection of the
National Institute for Communicable Diseases, South Africa
(H442, SPU116/89, and AR381/00) (Table 1). Low passage
lineage 1 strains were obtained either as freeze-dried or as
wet cell culture supernatant fluid from Drs. R.E. Shope and
D.W.C. Beasley of the University of Texas Medical Branch,
Galveston (NY385/99, AN4766, and Kunjin MRM16), and
Dr. Cinnia Huang of the Wadsworth Center, New York
Department of Health, Albany (NY2001Hu). The viruseswere passaged once in Vero cell cultures, and working
stocks titrated in the same cells for use in the experiments
described here.
Mouse neuropathogenicity experiments
Groups of five 3- to 4-week-old male NIH Swiss mice
were inoculated intraperitoneally (ip) or intracerebrally (ic)
with 10-fold dilutions of the WNV strains calculated to
contain 0.1–10,000 50% cell culture infectious doses
(TCID50) per inoculum volume of 20 Al, as described
previously (Beasley et al., 2002). Dilutions were performed
in serum-free Liebowitz cell culture medium, and a group of
control mice was mock-infected with diluent. Deaths were
recorded over 14 days of observation, 50% lethal dose
(LD50) end-points were calculated for each titration, and the
LD50 for each WNV strain expressed in TCID50 (Beasley et
al., 2002; Lynnette and Schmitt, 1979).
Measurement of differential gene expression in
WNV-infected mice
For each strain, groups of 5 mice were inoculated
subcutaneously with 10,000 TCID50 of virus, while a
control group was mock-infected with diluent. Three mice
in each group were sacrificed on day 5 post-inoculation, and
the brain, spleen, and liver were harvested for RNA
isolation. The left hemisphere of the brain, and pieces of
spleen and liver were immediately placed in RNA-later
(Qiagen, Hilden, Germany), and stored at 80 -C until
extracted. The remaining 2 mice were monitored to
determine survival time.
Extraction of RNA
RNA was extracted with a monophasic solution of
phenol and guanidine isothiocyanate (Trizol Reagent,
Invitrogen, Carlsbad, CA) and chloroform. The aqueous
phase was mixed with an equal volume of 70% ethanol and
applied to an RNeasy column (Qiagen, Hilden, Germany)
for final purification according to the manufacturer’s
instructions.
Preparation of labeled cDNA and microarray hybridization
Equal quantities of total RNA from mice in each
infection group were pooled for each organ to be processed
(see below) and hybridized to the microarray in competition
with a similarly processed reference RNA pool consisting of
equivalent amounts of RNA from all organs and infections.
The mock-infected control mice were treated as an
independent infection group. Fluorescent-labeled cDNA
was prepared by reverse transcription and direct incorpo-
ration of either dUTP-Cy3 or dUTP-Cy5 as detailed at:
http://www.niaid.nih.gov/dir/services/rtb/docs/LABELING.
PDF. cDNAs were hybridized to microarrays produced by
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Allergy and Infectious Diseases, Bethesda, MD, USA,
using Qiagen Array-Ready Oligo Set Mouse Version 2.
oligonucleotide probes (http://www.omad.qiagen.com/
download/storage/mouse_V2.0.2_genelist_s-.xls.gz) repre-
senting 16,463 predicted genes in the Refseq and Unigene
(Build Mm102) databases (http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GPL1057).
Image processing and data normalization
At least 3 hybridization replicates were performed for
each infection group, including one dye swap. Microarray
spots were imaged using an Axon GenePix 4000B
fluorescence scanner, and quantitated using Axon GenePix
Pro software version 4.0.1. To determine the mean
expression value for each gene, expression ratios were
calculated as the feature pixel median minus background
pixel median for one color channel, divided by the same for
the other channel. In cases where more than 10% of the
feature pixels were saturated, the feature pixel mean was
used instead of the median. When the feature pixel mean did
not exceed the background pixel mean by more than 2
standard deviations (calculated from the background pixel
distribution), the feature pixel median was used in the ratio
without background subtraction. In cases where both color
channels were near background (same criterion), the ratio
value was set to Fmissing_. Expression ratios were trans-
formed to the log base 2 for calculations to estimate
reproducibility. For each array, the overall signal in the two
channels was balanced by non-linear regression (Loess
Normalization). SAS software PROC LOESS (SAS Insti-
tute, Cary, NC, USA) was used with the following
parameters to fit Expression Change (defined above) against
the average signal for both channels: smooth = 0.7, degree =
1, iterations = 10. This method seeks to balance both
fluorescence channels by setting the average Expression
Change to zero at every level of average signal. Utilizing the
assumption that the overwhelming majority of spots will
have Expression Change equal to zero, the method seeks to
correct for bias due to differences in dye performance and
other systematic inequalities between the two fluorescence
channels that might be dependent on the magnitude of the
fluorescence signal.
Selection of genes with altered expression in infected mice
relative to mock infection
Each gene in each infection group that had at least 2 non-
missing measurements was subjected to a Student’s t test
(SAS, PROC ANOVA) to detect large expression differ-
ences relative to the mock-infected group. A P value cutoff
of 0.01 was used for each comparison, without adjustment
for multiple testing (considering the number of strains or the
number of genes on the array). Results were expressed for
each strain and each organ separately as the meanexpression relative to mock-infected. The data were
subjected to a second round of filtering to include only
genes for which at least 1 strain had a mean absolute value
relative to mock of 2-fold change or 1/2 and that was
Fpresent_ in at least 60% of the strains using the program
Cluster (Michael Eisen, Stanford University, 1998).
Selection of genes with increased expression in the more
highly neuroinvasive infections
WNV strains were classified as either highly neuro-
invasive or less neuroinvasive based on the LD50 results
obtained in ip titration of virus in mice. Strains AN4766,
AR381/00, and MRM16 (Kunjin) were classified as less
neuroinvasive and the other four strains as more highly
neuroinvasive (Table 1). A t test for expression differences
between the two virus groups was used to select genes
with precise (low error) measurements and relatively large
differences. A P value cutoff of 0.001 (uncorrected for
multiple testing or lack of independence for measurements
within the same treatment group) and a log2 ratio of T0.71
were used to select genes for further interpretation. Log2
values were transformed to absolute values so that a log2
ratio of 0.71 will be presented as a magnitude fold change
of 1.64 and a log2 ratio of 0.71 decrease relative to
mock be presented as 1/1.64 = 0.611 in Tables 2A, B, C.
An arbitrary cutoff value of 1.64 was used instead of the
usual 2 to select genes that were differentially expressed in
highly relative to less neuroinvasive strains to insure
inclusion of all significant genes that were important in
pathogenic WNV infection following manual inspection of
the statistically filtered gene list and ‘‘in-silico’’ literature
confirmation of data.
Quantitative real-time reverse transcriptase-polymerase
chain reaction
A quantitative reverse transcriptase-polymerase chain
reaction (RT-PCR) was used to verify the microarray
measurements for 5 selected genes in brain tissue, as well
as to determine the level of WNV replication in each of the
organs studied, brain, liver, and spleen, using the same
RNA pools from WNV infection groups as used for
hybridization. A 1-Ag portion of RNA from mouse brain,
liver, and spleen was used to synthesize cDNA with AMV
reverse transcriptase and random hexamer primers (Roche
Molecular Biochemicals, Mannheim, Germany). Quantita-
tive PCR was performed by kinetic quantification relative
to the mouse porphobilinogen deaminase (PBGD) house-
keeping gene using the LightCycler (Roche Diagnostics,
Mannheim, Germany) as described in Roche Applied
Science, Technical Note LC13/2001 and LC15/2002.
Primers were designed with Primer 3 (http://www.frodo.
wi.mit.edu/cgi-bin/primer3/primer3.cgi) and selected to
have similar melting temperatures and to amplify ¨250-bp
regions of the following mouse mRNA transcripts:
M. Venter et al. / Virology 342 (2005) 119–140138PBGD, chemokine C–X–C motif ligand 11 (CXCL11,
also known as interferon-inducible T-cell a chemo-attractant,
I-TAC), signal transducer and activator of transcription 1
(Stat-1), apolipoprotein D (Apod), interferon regulatory
factor 1 (Irf1), and Scotin gene. Primer sequences are
available on request. Universal flavivirus primers, FU1 and
CFD2 (Kuno, 1998), specific to a conserved region of the
NS5 gene, were used in the RT-PCR to determine the level of
WNV replication in organs.
The PCR was performed with the LightCycler FastStart
DNA Master PLUS SYBR Green I kit (Roche Diagnostics,
Mannheim, Germany) according to the manufacturer’s
recommendations. In brief, 0.5 AM of each primer was
mixed with 4 Al of premix FastStart DNA Master PLUS
SYBR Green I and 1 Al of cDNA. For quantification and
melting curve analysis of CXCL11/ITAC, Stat-1, Apod,
Irf1, and Scotin gene expression, the following program
was used: 95 -C 10 min; (95 -C 10 s, 53 -C 10 s; 72 -C
10 s) 35; (95 -C 10 s ramp rate 20; 65 -C 30 s ramp rate
20; 95 -C 0 s ramp rate 0.2). Cycling conditions for WNV
RNA quantification were as follows: 95 -C 10 min; (95 -C
10 s; 55 -C 5 s; 72 -C 12 s) 35; (95 -C 10 s ramp rate
20; 65 -C 30 s ramp rate 20; 95 -C 0 s ramp rate 0.2). For
relative quantification, expression of each target gene was
measured with respect to the housekeeping gene PBGD in
each sample and the absolute concentration calculated
from a standard curve. Quantification analysis of target and
reference genes was based on the Second Derivative
Maximum method (Roche, technical note No.LC13/
2001). Melting curves were used to verify the specificity
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